NCT04814602View on ClinicalTrials.gov

Single-dose PK Assessment of Oral Proglumide in Those With Hepatic Impairment

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

March 30, 2021

Primary Completion Date

August 30, 2021

Study Completion Date

February 20, 2022

Conditions
Cirrhosis, Liver
Interventions
DRUG

Proglumide

CCK receptor antagonist

Trial Locations (1)

20007

Georgetown University, Washington D.C.

All Listed Sponsors
lead

Georgetown University

OTHER

NCT04814602 - Single-dose PK Assessment of Oral Proglumide in Those With Hepatic Impairment | Biotech Hunter | Biotech Hunter